RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:251579

Giant cell glioblastoma

low confidenceSubtype of disorder

Publications

652

Trials

99

Interventional, condition-specific

Researchers

1,399

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

Monstrocellular sarcoma [obs]

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    652 matched papers (406 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    99 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

652

652 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

652 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

406 in the last 10 years · low confidence

Phrase hits: 652 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,399

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Li S6 papers · 2026

    Centre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.

    Papers in Europe PMC
  2. 02
    Chen J5 papers · 2024

    Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

    Papers in Europe PMC
  3. 03
    Li Y5 papers · 2026

    College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China.

    Papers in Europe PMC
  4. 04
    Wang X5 papers · 2026

    Department of Neurosurgery, Xinhua Hospital of Shanghai Jiaotong University School of Medicine, the Cranial Nerve Disease Center of Shanghai Jiaotong University, Shanghai, China.

    Papers in Europe PMC
  5. 05
    Chen H4 papers · 2025

    Department of Neurosurgery, The First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.

    Papers in Europe PMC
  6. 06
    Chen Z4 papers · 2025

    Department of Neurosurgery, Xinhua Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, China.

    Papers in Europe PMC
  7. 07
    Pietsch T4 papers · 2024

    Department of Neuropathology, Institute of Neuropathology, Brain Tumor Reference Center, University of Bonn, Bonn, Germany.

    Papers in Europe PMC
  8. 08
    Sun Y4 papers · 2021

    Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. sunyunsy06@163.com.

    Papers in Europe PMC
  9. 09
    Wang Y4 papers · 2026

    School of Life Course and Population Sciences, King's College London, London, UK.

    Papers in Europe PMC
  10. 10
    Wang Z4 papers · 2026

    Department of Orthopaedic Surgery, Chungnam National University School of Medicine, Daejeon, Republic of Korea.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

99

interventional trials for this specific condition

99 interventional trials matched this specific condition name; none in our sample are currently recruiting. 1,590 trials are registered for glioblastoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

99 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 98.4th percentile).

low confidence · 98.4th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

99 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Broader category: glioblastoma

1,590

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Giant cell glioblastoma" OR "Monstrocellular sarcoma [obs]"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Giant cell glioblastoma" OR "Monstrocellular sarcoma [obs]"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 99 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"glioblastoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (652) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T10:47:44.752Z